These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 27692902)

  • 1. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No association of DNM3 with age of onset in Asian Parkinson's disease.
    Foo JN; Tan LC; Au WL; Prakash KM; Liu J; Tan EK
    Eur J Neurol; 2019 May; 26(5):827-829. PubMed ID: 30133089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Gustavsson EK; Follett J; Trinh J; Barodia SK; Real R; Liu Z; Grant-Peters M; Fox JD; Appel-Cresswell S; Stoessl AJ; Rajput A; Rajput AH; Auer R; Tilney R; Sturm M; Haack TB; Lesage S; Tesson C; Brice A; Vilariño-Güell C; Ryten M; Goldberg MS; West AB; Hu MT; Morris HR; Sharma M; Gan-Or Z; Samanci B; Lis P; Periñan MT; Amouri R; Ben Sassi S; Hentati F; ; Tonelli F; Alessi DR; Farrer MJ
    Lancet Neurol; 2024 Jun; 23(6):603-614. PubMed ID: 38614108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
    Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
    J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
    Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
    Brown EE; Blauwendraat C; Trinh J; Rizig M; Nalls MA; Leveille E; Ruskey JA; Jonvik H; Tan MMX; Bandres-Ciga S; Hassin-Baer S; Brockmann K; Infante J; Tolosa E; Ezquerra M; Ben Romdhan S; Benmahdjoub M; Arezki M; Mhiri C; Hardy J; Singleton AB; Alcalay RN; Gasser T; Grosset DG; Williams NM; Pittman A; Gan-Or Z; Fernandez-Santiago R; Brice A; Lesage S; Farrer M; Wood N; Morris HR;
    Neurobiol Aging; 2021 Jan; 97():148.e17-148.e24. PubMed ID: 32873436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
    Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
    Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease.
    Berge-Seidl V; Pihlstrøm L; Wszolek ZK; Ross OA; Toft M
    Neurobiol Aging; 2019 Feb; 74():236.e1-236.e5. PubMed ID: 30340792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Sadhukhan D; Biswas A; Bhaduri A; Sarkar N; Biswas A; Das SK; Banerjee TK; Ray K; Ray J
    Indian J Med Res; 2020 Jun; 151(6):592-597. PubMed ID: 32719233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
    Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors.
    Lüth T; König IR; Grünewald A; Kasten M; Klein C; Hentati F; Farrer M; Trinh J
    Mov Disord; 2020 Oct; 35(10):1854-1858. PubMed ID: 32875616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for prehistoric origins of the G2019S mutation in the North African Berber population.
    Ben El Haj R; Salmi A; Regragui W; Moussa A; Bouslam N; Tibar H; Benomar A; Yahyaoui M; Bouhouche A
    PLoS One; 2017; 12(7):e0181335. PubMed ID: 28723952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolution of Genetic Variability at the
    Guenther DT; Follett J; Amouri R; Sassi SB; Hentati F; Farrer MJ
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Lüth T; Gabbert C; Koch S; König IR; Caliebe A; Laabs BH; Hentati F; Sassi SB; Amouri R; Spielmann M; Klein C; Grünewald A; Farrer MJ; Trinh J
    Mov Disord; 2023 Oct; 38(10):1837-1849. PubMed ID: 37482924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.